Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Gonorrhea Therapeutics Market Grown from 2024 to 2025?
The market size for gonorrhea therapeutics has seen robust growth in the past few years. The market which stood at $1.88 billion in 2024 is forecasted to expand to $1.98 billion in 2025, a compound annual growth rate (CAGR) of 5.4%. The historical growth is credited to factors such as Neisseria gonorrhoeae’s growing resistance, an increased prevalence of gonorrhea and antimicrobial resistance (AMR), a rise in antibiotic resistance, and a surge in the use of dual therapy treatments.
What Growth Rate Is Anticipated for the Gonorrhea Therapeutics Market in the Coming Years?
In the forthcoming years, the market size for gonorrhea therapeutics is predicted to witness substantial growth, elevating to $2.42 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 5.2%. The expansion during this forecast period can be associated with the escalating number of sexually transmitted infections, an enhanced focus on tailor-made medicine, the emergence of antibiotic resistance, an increasing occurrence of gonorrhea, and an elevated demand for efficient treatments. Significant trends during this period are expected to include technological advancements, high-level diagnostic tests, the formulation of new therapeutics, the introduction of combined treatment methods, and regulatory backing for accelerated drug sanctioning processes.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21195&type=smp
Who Are the Leading Companies in the Gonorrhea Therapeutics Market?
Major companies operating in the gonorrhea therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc, Becton Dickinson and Company, Hologic Inc., Aurobindo Pharma Limited, Innoviva Inc., Debiopharm Group, Achilles Vaccines S.r.l., Melinta Therapeutics LLC, VenatoRx Pharmaceuticals Inc., Evofem Biosciences Inc., Recce Pharmaceuticals Ltd., Therapyx Inc., Entasis Therapeutics Inc., Apotex Inc., Alopexx Pharmaceuticals LLC, Summit Therapeutics Inc.
What Are the Key Drivers of the Gonorrhea Therapeutics Market?
The rise in sexually transmitted infections is anticipated to boost the development of the gonorrhea therapeutics market. Sexually transmitted infections (STIs) are spread through sexual contact and can be caused by bacteria, viruses, or parasites. The escalation in STIs can be linked to factors such as unprotected sex, inadequate awareness or education, an increased number of sexual partners, low usage of condoms, and tardy or insufficient testing and treatment. Gonorrhea therapeutics are utilized to address STIs by combating the neisseria gonorrhoeae bacteria, thus preventing further complications and transmission. As an example, a report released by the National Institute for Public Health and the Environment, a government agency based in the Netherlands, in June 2024, indicated a significant yearly rise in the number of gonorrhea cases diagnosed at SHCs, escalating from 10,600 in 2022 to 13,853 in 2023. This implies a 31% growth. Consequently, the rise in sexually transmitted infections is fueling the expansion of the gonorrhea therapeutics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21195&type=smp
What Are the Key Market Segments in the Gonorrhea Therapeutics Industry?
The gonorrhea therapeutics market covered in this report is segmented –
1) By Therapeutic Class: Antibiotics, Combination Therapy, Monotherapy
2) By Route Of Administration: Oral, Intravenous, Intramuscular
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Clinics, Home Care
Subsegments:
1) By Antibiotics: Beta-lactams, Macrolides, Fluoroquinolones, Aminoglycosides
2) By Combination Therapy: Dual Antibiotic Therapy, Triple Antibiotic Therapy
3) By Monotherapy: Single Antibiotic Treatment, Other Monotherapy Options
What Are the Latest Trends in the Gonorrhea Therapeutics Market?
Companies leading in the gonorrhea therapeutics sector are producing imaginative items, like the rapid polymerase chain reaction (PCR) tests, to offer immediate, precise pathogen detection and their characteristics, including antibiotic resistance, during care provision. A rapid PCR test is a diagnostic procedure that swiftly enlarges and identifies particular DNA or RNA sequences, facilitating speedy pathogen or genetic content identification. In a case of February 2024, Visby Medical, Inc., a medical technology organization from the US, introduced a gonorrhea exam inclusive of an antimicrobial resistance evaluation. This fast diagnostic exam is created to identify the existence of Neisseria gonorrhoeae, the bacteria causing gonorrhea, and examine its susceptibility to ciprofloxacin, an antibiotic where some gonorrhea strains have shown resistance. This exam is a component of a mobile, tool-free PCR platform, facilitating instant testing during care provision. It was developed under funding from the US non-profit entity CARB-X, and the organization has intentions of broadening the exam to comprise the detection of other STIs, such as Chlamydia trachomatis and Trichomonas vaginalis, among males.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/gonorrhea-therapeutics-global-market-report
What Are the Key Regional Markets in the Gonorrhea Therapeutics Industry?
North America was the largest region in the gonorrhea therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gonorrhea therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21195
This Report Delivers Insight On:
1. How big is the gonorrhea therapeutics market, and how is it changing globally?
2. Who are the major companies in the gonorrhea therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the gonorrhea therapeutics market right now?
4. Which products or customer segments are growing the most in the gonorrhea therapeutics market?
5. What factors are helping or slowing down the growth of the gonorrhea therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model